All News
Predicting Treatment Response in Inflammatory Muscle Disorders
Rheumatologists looking for clues to whether their patients with certain inflammatory myopathies will improve on immunosuppressive drugs may find them in a new study appearing in Arthritis Care & Research.
Read Article
BMI Most Impairs Treatment Response in Rheumatoid Arthritis
Using a large cohort of rheumatoid arthritis (RA) patients, Tumor-Necrosis Factor inhibitors (TNFi) were compared to non-TNFi biologic therapies and showed that poorer responses were seen in obese and underweight patients, with no clear superiority of non-TNFi therapy over TNFi therapy in an
Read Article
CV Risk Management in Rheumatic Disease Patients
The European League against Rheumatism (EULAR) has developed recommendations for cardiovascular risk (CVR) management in rheumatic disease patients based on literature review and expert consensus.
Read Article
Rheumatoid Arthritis Nonadherence is Multifactorial
The consequences of medication non-adherence (NA) in rheumatoid arthritis (RA) care are numerous and damaging. A 6-month prospective cohort study of RA patients shows NA to vary according to drug type and be related to psychological, communicational, logistic, sociodemographic or clini
Read Article
Hand OA and Heroes in Rheumatology (2.11.2022)
Interesting reports this week about dementia, who gets hand OA and a great list of women Heroes and Pillars of Rheumatology. Tune in as Dr. Jack Cush reviews the news and journal articles from this past week in RheumNow.com.
Read Article
Hand Pain Related to Obesity and Inflammatory Markers
Arthritis & Rheumatology has published the results of the Nor-Hand study, showing that pain hand osteoarthritis (OA) was related to a higher body mass index (BMI) and also to inflammatory adipokines, such as leptin.
Read Article
Links:
Why Would Hand OA Be Less Severe in Black People?
Osteoarthritis (OA) of the hand was less severe according to objective and pain-related markers in Black patients versus those of other racial/ethnic groups after adjustment for known risk factors, researchers found.
Read Article
Vitamin D and the Risk of Autoimmune Diseases
The results of the VITAL study (presented at ACR 2021) are now published by BMJ, showing that vitamin D and omega 3 fatty acids reduce the overall risk of autoimmune disease (AID) in a population based intervention trial.
Read Article
Links:
Dr. John Cush RheumNow ( View Tweet)
Methotrexate Side Effects
Data came from the UK Rheumatoid Arthritis Medication Study (RAMS), a prospective cohort of early RA patients starting methotrexate (MTX) shows that in the first year, adverse events (AE) were common, but not serious.
Read Article
X-Linked Hypophophatemia - Survey Results
The July 2021 RheumNow “Live Vote” surveyed US and non-US rheumatologists on their knowledge and practices when dealing with the bone disorder, X-linked hypophosphatemia (XLH).
Read Article
An Ounce of Prevention (2.4.2022)
Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com. He discusses the GI side effects of IL-17 inhibitors, downstream revenues from rheumatology care and dietary prevention of gout.
Read Article
Pediatric Rheumatology Workforce Shortages
Two recent analyses from the USA and Canada point to a significant unmet need with regard to pediatric rheumatologists.
Read Article
ACR/EULAR 2022 Classification Criteria for Microscopic Polyangiitis
The 2022 ACR/EULAR classification criteria for microscopic polyangiitis (MPA) have been developed, validated and are now ready for use in clinical research.
Read Article
Healthy Diets Prevent Gout in Women
A prospective cohort from the Nurses’ Health Study has demonstrated that eating a healthy diet results in a 12% to 32% lower risk of incident gout and an even greater risk reduction (65% to 68%) when combined with normal weight and avoiding diuretics.
Read Article
ACR Newly Revised COVID-19 Vaccine Clinical Guidance for RMD Patients
The ACR has updated its clinical guidance for the use of COVID-19 vaccination in patients with musculoskeletal disorders (MSK).
Read Article
The Last Word on JAK Inhibitor Safety & 1133 Study (1.28.2022)
Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com. This week a trifecta of Gout reports and the last word on the ORAL Surveillance study...
Read Article
Risk vs. Benefit Lessons from the ORAL Surveillance Study
In an editorial in the current edition of the NEJM, Dr. Jasvinder Singh comments on the Oral Surveillance trial (Ytterberg et al.), a 4-year randomized, open-label, noninferiority, postauthorization, safety end-point trial, in high risk active rheumatoid arthritis patients over age 50 years.
Read Article
MMWR: Booster Vaccine Efficacy in Immunosuppressed Patients
For adults aged ≥18 years who received 2 doses of an mRNA COVID-19 vaccine, a third dose increased vaccine effectiveness (prevention of hospitalization) among adults without (82% to 97%) and with immunocompromising conditions (69% to 88%), with near similar efficacy.
Read Article